舌下减敏疗法治疗鳞茎过敏成效高

纽约（路透社健康专栏）12同月21日电—据《变态反应，肾病及生物学年鉴》杂志11同周刊一篇引述，舌下减敏临床（SLIT）化疗花朵持续性的呼吸道过敏成效极低。“依靠SLIT减少鼻塞的并发症及用药消费，消除社会制度经济负担，”比利时Genoa大学Giovanni Passalacqua哈佛大学却说。“先前已经有大幅提高注射临床消除社会制度负担，但这是首次对新颖临床（SLIT）展开严格评估的结果。”Passalacqua哈佛大学及其老友们对花朵持续性的过敏性鼻塞和肾病治果展开科学研究，评估依靠SLIT融合准则化疗及直接依靠准则化疗的费用及。科学研究管理人员引述，SLIT使63.1%的病症副作用有所改善，并预防措施51.8%的病症显现肾病，而直接广泛应用准则临床仅仅使23.2%的病症副作用有所改善，预防措施28.9%的病症显现肾病。而且同准则化疗比起，SLIT的直接及间接耗费均降低：SLIT病症化疗的总体耗费低于发展中国家医疗保健系统对预测的4年末直接用药化疗耗费，并且低于社会制度公众预测的2年末直接用药化疗耗费。“SLIT并很难算是大幅提高注射临床的竞争者，” Passalacqua哈佛大学解释却说，“而是将其作为化疗方法的另一选项。它第二大的优点在于其最优的稳定性和病症的易接受性。”“SLIT在美国没有正式广泛应用，尽管一些变态反应专家广泛应用它（并且获得了满意的结果），” Passalacqua哈佛大学却说。“欧洲情况实质上不同，SLIT在很多发展中国家中都飞速发展（如比利时，德国，法国，西班牙，波尔图，希腊及匈牙利）。”当前的弊端是SLIT没有得到FDA的批复，“Passalacqua哈佛大学补充道。“受到FDA支持的临床科学研究正在展开中都，并有望得到批复。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma Max Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.

主笔：黄色幻想